Jyong Biotech (MENS) Stock Analysis

What Jyong Biotech does

Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.

Key metrics

ETFs linked to MENS

Broad-market and Healthcare sector ETFs an investor holding Jyong Biotech is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MENS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Jyong Biotech?

Jyong Biotech trades under the ticker MENS on NASDAQ.

Which exchange is MENS listed on?

MENS is listed on NASDAQ.

What sector does Jyong Biotech operate in?

Jyong Biotech is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MENS in a portfolio?

PortView shows MENS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.